Skip to main content

Biomarker out-licensing

SphingoTec has established an extended intellectual property portfolio covering biomarkers and its clinical utility for acute care conditions such as sepsis, acute heart failure, and acute kidney injury. The proprietary biomarker portfolio includes bioactive Adrenomedullin 1-52 (bio-ADM*), a biomarker for real-time assessment of endothelial function in conditions like sepsis, and Proenkephalin A 119-159 (penKid*), a biomarker for real-time assessment of kidney function. The biomarker portfolio is available for licensing to companies wishing to develop assays for clinical use on their immunoassay platforms.

Bio-ADM: endothelial function biomarker

Bio-ADM is a dynamic biomarker for the real-time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock and subsequent organ failure in critically ill patients.

Discover more

PenKid: kidney function biomarker

PenKid is a dynamic biomarker for the real time assessment of kidney function. PenKid is a blood-based alternative to standard biomarkers that correlates with the true glomerular filtration rate (true GFR).

Discover more

Contact us

Do you have any questions or require more information?
We are looking forward to talking to you!

email: info[at]

Deborah Bergmann

Managing Director & CEO


Sphingotest® penKid®, and sphingotest® bio-ADM® are offered for in vitro diagnostics. “penKid” and “bio-ADM” represent the analytes Proenkephalin A 119-159 and bioactive Adrenomedullin 1-52, respectively.